Depression
Conditions
Keywords
TMS, Treatment, Adolescents, Safety, Efficacy
Brief summary
This is a study to assess the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) as a treatment for depressed 13-18 year olds. In rTMS high-intensity, fluctuating magnetic fields non-invasively stimulate the cortex of the brain depolarizing neurons. No anesthetic is required and the treatment in subconvulsive. Recent studies suggest that rTMS can be an effective treatment for depressive illness in adults (Loo and Mitchell, 2005) and appears to be quite safe. Minimal data of TMS use in adolescents psychiatric disorders. Data only existed in seven patients of the four that were depressed two showed improvement in their depression (Quintana, 2005). No sham-controlled studies have been conducted. The investigators wish to assess this in a sham-controlled study of 30 adolescents. The investigators hypothesize that rTMS will have an antidepressant effect and produce no neuropsychological impairment.
Detailed description
The study has two phases: the sham-controlled phase and an open phase. Sham-controlled Phase Participants are randomly assigned to an active or sham TMS condition. Open Phase Following the sham controlled period participants participants in the sham rTMS condition will be offered active rTMS. Participants will have the opportunity to receive up to 6 weeks of active rTMS.
Interventions
DEVICETranscranial Magnetic Stimulation
Sponsors
University of Sydney
Monash University
The University of New South Wales
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
13 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* DSM-IV Major Depressive Episode of no more then 3 years. * Montgomery-Asberg Depression Rating Scale score of 20 or more. * Aged between 13 and 18. * May or may not be taking antidepressant medication.
Exclusion criteria
* Patient (or family is patient is under 18)not able to give informed consent. * Failure to respond to ECT in current or past episodes of depression. * Significant other Axis 1 psychiatric disorders e.g. schizophrenia. * In imminent physical or psychological danger and needs a rapid clinical response due to inanition, psychosis or high suicide risk. * Drug or alcohol abuse currently or in the last month. * History of neurological illness e.g. epilepsy; neurosurgical procedure * Mental in the cranium, a pacemaker, cochlear implant, medication pump or other electronic device. * Women of child-bearing age whom pregnancy cannot be ruled out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All measures at baseline and at the end of each week of treatment in the blind phase and after every 2 weeks of treatment in the open phase. | — |
| Montgomery-Asberg Depression Rating Scale (MADRS) | — |
| Clinical Global Impressions Scale (CGI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Tower of London | — |
| Verbal Fluency | — |
| All measures at baseline, at the end of the 4 week blind phase and at end of treatment in the open phase. | — |
| Beck Depression Inventory | — |
| Centre for Epidemiological Studies - Depression - Child (CES-DC) scale | — |
| Trail A, B | — |
| Rey Auditory Verbal Learning Test (RAVLT) | — |
| Digit span forwards and backwards and Digit symbols (WAIS) | — |
Countries
Australia
Outcome results
None listed